EMTRICITABINE

作品数：31被引量：31H指数：3
导出分析报告
相关领域：医药卫生更多>>
相关作者：李玮宋宏锐更多>>
相关机构：沈阳药科大学更多>>
相关期刊：《Hepatobiliary & Pancreatic Diseases International》《Chinese Medical Journal》《药学进展》《Open Journal of Physical Chemistry》更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations
《Chinese Medical Journal》2024年第22期2758-2760,共3页Ziwei Chang Hongyan Zhu Yiting Zhang Yaling Chen Jiahui Li Jiamin Qin Yueping Zhu Hongxia Wei Yongfeng Yang Meiyin Zou Feng Qian Zhiliang Hu 
This study was funded in part by the project of Nanjing Infectious Disease Clinical Medical Center and the project of Innovation center for infectious disease of Jiangsu Province(NO.CXZX202232);the Jiangsu Provincial Health Commission Medical Research Foundation(No.M2022030);the Nanjing Medical Science and Technique Development Foundation(No.ZKX21037);the Research Project of Nantong Municipal Health Commission(No.MS2023077).
To the Editor:China provides free antiretroviral therapy(ART)for people with human immunodeficiency virus(HIV),typically using two nucleoside reverse transcriptase inhibitors(NRTIs)and one non-nucleoside reverse trans...
关键词：mortality REGIMEN resistance 
Clinical efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide and lamivudine/dolutegravir in the treatment-naive patients with acquired immunodeficiency syndrome
《China Medical Abstracts(Internal Medicine)》2024年第3期157-157,共1页WANG Jiangrong 
Objective To analyze the efficacy and safety of integrase inhibitor-based single-tablet regimens bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and lamivudine/dolutegravir (3TC/DTG) in the treatment-naive p...
关键词：PATIENTS immunodeficiency TREATMENT 
Changes in blood lipid levels and influencing factors among treatment-naïve adult male HlV/AlDS patients following BlC/FTC/TAF vs.3TC+EFV+TDF
《Chinese Medical Journal》2024年第12期1447-1452,共6页Xi Wang An Liu Zaicun Li Hongwei Zhang Ruojun Esther Wu Ying Shao Jianwei Li Jiangzhu Ye Wei Liu Lijun Sun 
supported by the Gilead Sciences and the Capital Health Research and Development of Special Fund(No.2022-1G-3015)
Background:Antiretroviral therapy(ART)was often associated with dyslipidemia among human immunodeficiency virus(HIV)/acquired immunodeficiency syndrome(AIDS)patients.This study aimed to assess treatment-naïve adult ma...
关键词：Antiretroviral therapy Blood lipids Bictegravir/emtricitabine/tenofovir alafenamide Lamivudine efavirenz and tenofovir disoproxil fumarate BIC/FTC/TAF 3TC+EFV+TDF HIV AIDS 
Efficacy and safety profiles of dolutegravir plus lamivudine vs.bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1被引量：1
《Chinese Medical Journal》2023年第22期2677-2685,共9页Yinghua Wei Jin Li Ruhong Xu Li Wen Yiming Deng Lixia He Huijun Zhong Yanhao Wang 
Background:Dual regimen dolutegravir(DTG)plus lamivudine(3TC)has demonstrated non-inferior efficacy compared to DTG-based three-drug regimens(3DRs),yet directly comparative data regarding the efficacy and safety of DT...
关键词：HIV-1 Antiretroviral therapy Dolutegravir Bictegravir Efficacy Safety Target not detected 
Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China:a real-world assessment
《Chinese Medical Journal》2023年第22期2738-2740,共3页Yongquan Peng Xujian Cao Yating Wang Weiwei Yu Ziwei Zeng Min Wang 
supported by the Research project of Hunan Provincial Department of Science and Technology(No.2020SK21361)
To the Editor:Human immunodeficiency virus(HIV)epidemic poses a significant challenge to global public health.As of 2022,approximately 39.0 million people worldwide were living with HIV.[1]With the ongoing evolution o...
关键词：REGIMEN drugs approval 
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection(GEMINI-1 and GEMINI-2):week 48 results from two multicentre,double-blind,randomised,non-inferiority,phase 3 trials
《四川生理科学杂志》2023年第10期1852-1852,共1页Pedro Cahn 
Background:Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy(ART).We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared w...
关键词：regimen infection centre 
An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1被引量：2
《Chinese Medical Journal》2022年第22期2725-2729,共5页An Liu Ruolei Xin Hongwei Zhang Lili Dai Ruojun(Esther)Wu Xi Wang Aixin Li Wei Hua Jianwei Li Ying Shao Yue Gao Zhangli Wang Jiangzhu Ye Gulimila A bu dou re xi ti Zaicun Li Lijun Sun 
Gilead Sciences, including provision of the study drug, and the Capital Health Research and Development of Special Fund(No. 2022-1G-3015)。
Background: Single-tablet regimen (STR) provides a convenient once-daily regimen for the prevention of human immunodeficiency virus (HIV) infection. Here, we investigated the safety and tolerability of coformulated bi...
关键词：Post-exposure prophylaxis Human immunodeficiency virus Bictegravir/emtricitabine/tenofovir alafenamide Adverse event 
Advantages of switching to elvitegravir/cobicistat/emtricitabine/ tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome
《Chinese Medical Journal》2022年第22期2747-2749,共3页Lina Fan Lei Li Liying Gao Yue Hu Aiping Yu Defa Zhang Chunting Qiu Rong Huang Yue Wu Ping Ma 
This work was funded by grants from the Tianjin Key Medical Discipline (Specialty) Construction Project (No. ZD02);the Tianjin Science and Technology Cultivation Project (No. RC20019)。
To the Editor:With recent advances in antiretroviral therapy(ART)regimens,many patients may benefit from switching drugs.The new combination drug,elvitegravir/cobicistat/emtricitabine/tenofovir(E/C/F/TAF),has been app...
关键词：IMMUNODEFICIENCY DRUGS treatment 
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV被引量：5
《Chinese Medical Journal》2021年第23期2850-2856,共7页Huan Xia Xiao-Jie Huang Yue Hu Li-Ying Gao Yue Wu Hao Wu Zhong-Fang Yan Ping Ma 
the 13th Five-year National Major Project for HIV/AIDS and Hepatitis B Control and Prevention and the Chinese Ministry of Science and Technology(No.2017ZX10202102005004).
Background:Central nervous system(CNS)symptoms after efavirenz(EFV)treatment in people living with human immunodeficiency virus(HIV)could persist and impact their quality of life.We assessed the impact of EFV-based re...
关键词：HIV EFAVIRENZ Elvitegravir Tenofovir alafenamide Central nervous system 
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications被引量：3
《Chinese Medical Journal》2020年第23期2892-2893,共2页Rui Ma Qiang Zhang Yao-Shen Zhang Biao Xu Zhi-Wen Tong Chang-Song Zhao Ru-Gang Zhao 
This work was supported by the grants from the Capital’s Funds for Health Improvement and Research(No.2018-2-2174);Scientific Research Common Program of the Beijing Municipal Commission of Education(No.KM201810025029);the Beijing Municipal Science&Technology Commission(No.Z191100006619060)。
To the Editor:There are 1.25 million people living with human immunodeficiency virus(HIV)(PLWH)in China,with more than 135,000 newly diagnosed cases in 2018.[1]HIV-positive patients who suffer a fracture have extremel...
关键词：patients REGIMEN DRUGS 
全选清除导出
共4页<1234>
检索报告 对象比较 聚类工具 使用帮助 返回顶部